Equity Market Research
Monday, 4 December 2017
Mylan/ Biocon: Biosimilar- USD900m-1b opportunity in medium term says Motilal Oswal https://goo.gl/yKU93g
Mylan/ Biocon: Biosimilar- USD900m-1b opportunity in medium term says Motilal Oswal https://goo.gl/yKU93g
https://goo.gl/yKU93g
No comments:
Post a Comment
‹
›
Home
View web version
No comments:
Post a Comment